Amgen’s settlement with rival AbbVie gives it a timeline for the rollout of a biosimilar that mimics Humira, the world’s best-selling drug, but AbbVie still secured protections for its $16 billion-a-year golden goose. The Thousand Oaks-based company received Food and Drug Administration approval for its Humira biosimilar in September of 2016, and Chicago-based AbbVie filed…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
